Lyka Labs (LYKALABS) | Stock Overview & Key Data
Lyka Labs Performance Comparison
Stock Range
Today's Range
Low: ₹98.55
High: ₹101.89
on August 25, 2025
52 Week Range
Low: ₹96.80
High: ₹176.59
on April 7, 2025
on December 10, 2024
All-Time High: ₹267.00 on December 20, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR3.6B
EPS
2.10
P/E Ratio (TTM)
47.86
Forward P/E
N/A
P/B Ratio
3.46
PEG Ratio
-1.28
Div. Yield
N/A
ROE
7.73%
Beta
0.639
Debt to Equity
37.90
Financial Highlights
Profitability
Gross Margin
61.43%
Operating Margin
4.77%
Profit Margin
5.45%
Returns and Earnings
Return on Assets (TTM)
4.55%
Return on Equity (TTM)
7.73%
EBITDA
INR200.1M
Net Income (TTM)
INR74.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR38.61
Quarterly Revenue Growth (YoY)
9.70%
Quarterly Earnings Growth (YoY)
-35.20%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Lyka Labs LYKALABS | 3.61B Small-cap | 0.14% | -8.52% | -14.31% | -9.92% | -36.07% | -34.08% | -35.38% | 422.86% |
| Biocon BIOCON | 479.78B Large-cap | -1.19% | -8.68% | 8.30% | 12.06% | -2.40% | 0.24% | 21.77% | -14.49% |
| OneSource Specialty ONESOURCE | 212.97B Large-cap | 2.92% | -3.60% | 6.75% | 39.66% | 10.15% | 10.15% | 10.15% | 10.15% |
| Dishman Carbogen DCAL | 42.04B Small-cap | 6.31% | 11.88% | 2.89% | 29.89% | -1.95% | 37.76% | 132.64% | 50.89% |
| Zota Health Care ZOTA | 32.82B Small-cap | -9.12% | 2.79% | 23.33% | 45.25% | 54.94% | 87.10% | 365.15% | 725.42% |
| Panacea Biotec PANACEABIO | 25.00B Small-cap | -1.20% | -3.47% | -25.64% | 25.69% | -8.21% | 79.88% | 188.45% | 155.14% |
Ownership & Short Interest
Insider Ownership
59.69%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
36K
Average 90-Day Volume
40K
Lyka Labs Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Lyka Labs would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LYKALABS's 52-week high and low?
- In the last 52 weeks, Lyka Labs reached a high of ₹176.59 (on December 10, 2024) and a low of ₹96.80 (on April 7, 2025).
- What is the market cap and P/E ratio for LYKALABS?
- Curious about Lyka Labs's size and valuation? Its market capitalization stands at 3.61B. When it comes to valuation, the P/E ratio (trailing twelve months) is 47.86, and the forward P/E (looking ahead) is N/A.
- Does LYKALABS pay dividends? If so, what's the yield?
- As for dividends, Lyka Labs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Lyka Labs's main competitors or similar companies to consider before investing?
When looking at Lyka Labs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON479.78B Healthcare Biotechnology 0.24% 21.77% OneSource Specialty
ONESOURCE212.97B Healthcare Biotechnology 10.15% 10.15% Dishman Carbogen
DCAL42.04B Healthcare Biotechnology 37.76% 132.64% Zota Health Care
ZOTA32.82B Healthcare Biotechnology 87.10% 365.15% Panacea Biotec
PANACEABIO25.00B Healthcare Biotechnology 79.88% 188.45% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Lyka Labs Ltd? (e.g., ROE, Debt/Equity)
- To get a sense of Lyka Labs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.73%, the Debt to Equity ratio from the most recent quarter is 37.90, and its Gross Profit Margin stands at 61.43%.
- What is the recent revenue and earnings growth for LYKALABS?
- Looking at Lyka Labs's growth, its revenue over the trailing twelve months (TTM) was INR1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.70%, and quarterly earnings saw a YoY growth of -35.20%.
- How much of LYKALABS stock is held by insiders and institutions?
- Wondering who owns Lyka Labs stock? Company insiders (like executives and directors) hold about 59.69% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.